Annual EBITDA
-$196.70 M
+$133.66 M+40.46%
December 31, 2023
Summary
- As of February 7, 2025, DNLI annual EBITDA is -$196.70 million, with the most recent change of +$133.66 million (+40.46%) on December 31, 2023.
- During the last 3 years, DNLI annual EBITDA has fallen by -$267.95 million (-376.07%).
- DNLI annual EBITDA is now -376.07% below its all-time high of $71.25 million, reached on December 31, 2020.
Performance
DNLI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$120.92 M
-$6.27 M-5.47%
September 30, 2024
Summary
- As of February 7, 2025, DNLI quarterly EBITDA is -$120.92 million, with the most recent change of -$6.27 million (-5.47%) on September 30, 2024.
- Over the past year, DNLI quarterly EBITDA has dropped by -$6.27 million (-5.47%).
- DNLI quarterly EBITDA is now -149.11% below its all-time high of $246.20 million, reached on December 31, 2020.
Performance
DNLI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$496.05 M
-$9.34 M-1.92%
September 30, 2024
Summary
- As of February 7, 2025, DNLI TTM EBITDA is -$496.05 million, with the most recent change of -$9.34 million (-1.92%) on September 30, 2024.
- Over the past year, DNLI TTM EBITDA has dropped by -$9.34 million (-1.92%).
- DNLI TTM EBITDA is now -796.23% below its all-time high of $71.25 million, reached on December 31, 2020.
Performance
DNLI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
DNLI EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +40.5% | -5.5% | -1.9% |
| 3 y3 years | -376.1% | -19.4% | -50.2% |
| 5 y5 years | -404.9% | -19.4% | -50.2% |
DNLI EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +40.5% | -170.0% | +7.3% | -243.1% | at low |
| 5 y | 5-year | -376.1% | +40.5% | -149.1% | +7.3% | -796.2% | at low |
| alltime | all time | -376.1% | +40.5% | -149.1% | +7.3% | -796.2% | at low |
Denali Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$120.92 M(+5.5%) | -$496.05 M(+1.9%) |
| Jun 2024 | - | -$114.65 M(-11.9%) | -$486.71 M(+144.2%) |
| Mar 2024 | - | -$130.09 M(-0.2%) | -$199.29 M(+10.7%) |
| Dec 2023 | -$196.70 M(-40.5%) | -$130.40 M(+16.9%) | -$179.97 M(+19.3%) |
| Sep 2023 | - | -$111.58 M(-164.6%) | -$150.83 M(+4.3%) |
| Jun 2023 | - | $172.77 M(-256.0%) | -$144.60 M(-61.6%) |
| Mar 2023 | - | -$110.77 M(+9.4%) | -$376.71 M(+14.0%) |
| Dec 2022 | -$330.36 M(+15.0%) | -$101.25 M(-3.9%) | -$330.36 M(+8.6%) |
| Sep 2022 | - | -$105.34 M(+77.5%) | -$304.13 M(+7.8%) |
| Jun 2022 | - | -$59.34 M(-7.9%) | -$282.20 M(-0.1%) |
| Mar 2022 | - | -$64.42 M(-14.1%) | -$282.46 M(-1.6%) |
| Dec 2021 | -$287.16 M(-503.0%) | -$75.03 M(-10.0%) | -$287.16 M(-942.9%) |
| Sep 2021 | - | -$83.41 M(+39.9%) | $34.07 M(-42.8%) |
| Jun 2021 | - | -$59.61 M(-13.7%) | $59.51 M(-0.8%) |
| Mar 2021 | - | -$69.11 M(-128.1%) | $59.99 M(-15.8%) |
| Dec 2020 | $71.25 M | $246.20 M(-524.8%) | $71.25 M(-130.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$57.96 M(-2.0%) | -$230.65 M(+4.4%) |
| Jun 2020 | - | -$59.13 M(+2.2%) | -$220.96 M(-0.9%) |
| Mar 2020 | - | -$57.86 M(+3.9%) | -$222.95 M(+8.7%) |
| Dec 2019 | -$205.19 M(+426.7%) | -$55.70 M(+15.4%) | -$205.19 M(+183.5%) |
| Sep 2019 | - | -$48.27 M(-21.0%) | -$72.39 M(+21.1%) |
| Jun 2019 | - | -$61.12 M(+52.4%) | -$59.76 M(+10.3%) |
| Mar 2019 | - | -$40.10 M(-152.0%) | -$54.17 M(+39.0%) |
| Dec 2018 | -$38.96 M(-55.3%) | $77.10 M(-316.4%) | -$38.96 M(-71.9%) |
| Sep 2018 | - | -$35.64 M(-35.8%) | -$138.79 M(+11.3%) |
| Jun 2018 | - | -$55.53 M(+123.1%) | -$124.66 M(+37.1%) |
| Mar 2018 | - | -$24.89 M(+9.5%) | -$90.94 M(+4.5%) |
| Dec 2017 | -$87.06 M(+1.3%) | -$22.73 M(+5.7%) | -$87.06 M(+4.4%) |
| Sep 2017 | - | -$21.51 M(-1.3%) | -$83.42 M(+34.7%) |
| Jun 2017 | - | -$21.80 M(+3.8%) | -$61.91 M(+54.4%) |
| Mar 2017 | - | -$21.01 M(+10.1%) | -$40.10 M(+110.1%) |
| Dec 2016 | -$85.96 M(+419.2%) | -$19.09 M | -$19.09 M |
| Dec 2015 | -$16.56 M | - | - |
FAQ
- What is Denali Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Denali Therapeutics?
- What is Denali Therapeutics annual EBITDA year-on-year change?
- What is Denali Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Denali Therapeutics?
- What is Denali Therapeutics quarterly EBITDA year-on-year change?
- What is Denali Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Denali Therapeutics?
- What is Denali Therapeutics TTM EBITDA year-on-year change?
What is Denali Therapeutics annual EBITDA?
The current annual EBITDA of DNLI is -$196.70 M
What is the all time high annual EBITDA for Denali Therapeutics?
Denali Therapeutics all-time high annual EBITDA is $71.25 M
What is Denali Therapeutics annual EBITDA year-on-year change?
Over the past year, DNLI annual EBITDA has changed by +$133.66 M (+40.46%)
What is Denali Therapeutics quarterly EBITDA?
The current quarterly EBITDA of DNLI is -$120.92 M
What is the all time high quarterly EBITDA for Denali Therapeutics?
Denali Therapeutics all-time high quarterly EBITDA is $246.20 M
What is Denali Therapeutics quarterly EBITDA year-on-year change?
Over the past year, DNLI quarterly EBITDA has changed by -$6.27 M (-5.47%)
What is Denali Therapeutics TTM EBITDA?
The current TTM EBITDA of DNLI is -$496.05 M
What is the all time high TTM EBITDA for Denali Therapeutics?
Denali Therapeutics all-time high TTM EBITDA is $71.25 M
What is Denali Therapeutics TTM EBITDA year-on-year change?
Over the past year, DNLI TTM EBITDA has changed by -$9.34 M (-1.92%)